Strativa's development partner, bioalliance pharma, submits loramyc nda
Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. , announced that its development partner, BioAlliance Pharma, has submitted a New Drug Application to the Food and Drug Administration for Loramyc (miconazole Lauriad) 50mg mucoadhesive buccal tablets, as planned. If approved, Strativa could launch Loramyc in the second half of 2010. [more...]
|
|
|
